SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

11 Aug 2025 Evaluate
The Revenue for the quarter ended  June 2025 of Rs. 17469.00 millions grew by 11.56 % from Rs. 15658.60 millions.Net Profit recorded in the quarter ended June 2025 rise to 28.37% to Rs. 2620.40  millions  compared to R. 2041.30 millions in corresponding previous quarter.Operating profit for the quarter ended June 2025 rose to 4319.40 millions as compared to 3686.30 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 17469.00 15658.60 11.56 17469.00 15658.60 11.56 66779.20 61664.60 8.29
Other Income 250.20 153.90 62.57 250.20 153.90 62.57 712.90 1112.90 -35.94
PBIDT 4319.40 3686.30 17.17 4319.40 3686.30 17.17 15963.20 13226.70 20.69
Interest 120.60 194.20 -37.90 120.60 194.20 -37.90 630.40 1206.70 -47.76
PBDT 4198.80 3492.10 20.24 4198.80 3492.10 20.24 12517.40 10686.40 17.13
Depreciation 631.30 613.20 2.95 631.30 613.20 2.95 2519.70 2464.80 2.23
PBT 3567.50 2878.90 23.92 3567.50 2878.90 23.92 9997.70 8221.60 21.60
TAX 947.10 837.60 13.07 947.10 837.60 13.07 3490.10 2917.50 19.63
Deferred Tax 20.50 27.60 -25.72 20.50 27.60 -25.72 81.10 37.40 116.84
PAT 2620.40 2041.30 28.37 2620.40 2041.30 28.37 6507.60 5304.10 22.69
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 24.73 23.54 5.03 24.73 23.54 5.03 23.90 21.45 11.45

Ipca Laboratories Share Price

1530.60 -0.60 (-0.04%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×